Utilization in the Nordic countries of cancer medicines EMA approved 2008/14-2020: does it vary across countries?
Objective: To examine to what extent Norwegian cancer patients have benefited from new cancer medicines EMA approved after 2008 (and 14), as compared to the other Nordic countries. Method: based on sales data provided by IQVIA (for Sweden, Finland and Norway, 2008-2020) and DLIMI (for Denmark, 2015-...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Dissertation |
| Sprache: | eng |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Schreiben Sie den ersten Kommentar!